Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure

Journal of Thoracic Disease

Volumn 4, Issue 3, 2012, Pages 310-315

  Zeng, Qiaojun ^a   Jiang, Shanping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Beta blockers; Chronic heart failure; Chronic obstructive pulmonary disease

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MUSCARINIC RECEPTOR BLOCKING AGENT; VALSARTAN;

ABNORMAL RESPIRATORY SOUND; AGE DISTRIBUTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BRONCHOSPASM; CARDIOSELECTIVITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; LUNG FUNCTION TEST; NONHUMAN; OXYGEN THERAPY; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SPUTUM CULTURE; THORAX RADIOGRAPHY;

EID: 84864465267     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.01.09     Document Type: Review

References (34)

1. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130-9.
2. Suskovic S, Kosnik M, Lainscak M. Heart failure and chronic obstructive pulmonary disease: Two for tea or tea for two? World J Cardiol 2010;2:305-7.
3. Chhabra SK, Gupta M. Coexistent chronic obstructive pulmonary diseaseheart failure: mechanisms, diagnostic and therapeutic dilemmas. Indian J Chest Dis Allied Sci 2010;52:225-38.
4. De Blois J, Simard S, Atar D, et al. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail 2010;16:225-9.
5. van der Molen T. Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. Prim Care Respir J 2010;19:326-34.
6. Lainscak M, Hodoscek LM, Düngen HD, et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr 2009;121:309-13.
7. Ukena C, Mahfoud F, Kindermann M, et al. The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. Int J Cardiol 2010;145:172-6.
8. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007;49:171-80.
9. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between betablockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010;55:1780-7.
10. Hawkins NM, Jhund PS, Simpson CR, et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010;12:17-24.
11. Boudestein LC, Rutten FH, Cramer MJ, et al. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009;11:1182-8.
12. Abdool-Gaffar MS, Ambaram A, Ainslie GM, et al. Guideline for the management of chronic obstructive pulmonary disease-2011 update. S Afr Med J 2011;101:63-73.
13. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91.
14. Diaz-Guzman E, McCarthy K, Siu A, et al. Frequency and causes of combined obstruction and restriction identified in pulmonary function tests in adults. Respir Care 2010;55:310-6.
15. Iversen KK, Kjaergaard J, Akkan D, et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 2010;12:685-91.
16. Alam MS, Haque DS, Amin MN. Role of Plasma B-type Natriuretic peptide in Diagnosis Heart Failure. Ibrahim Card Med J 2011;1:36-40.
17. Hannink JD, van Helvoort HA, Dekhuijzen PN, et al. Heart failure and COPD: partners in crime? Respirology 2010;15:895-901.
18. Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart 2011;97:411-6.
19. Rutten FH, Vonken EJ, Cramer MJ, et al. Cardiovascular magnetic resonance imaging to identify left-sided chronic heart failure in stable patients with chronic obstructive pulmonary disease. Am Heart J 2008;156:506-12.
20. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available online: http://www.goldcopd.org/.
21. Clark AL, Johnson MJ, Squire I. Does home oxygen benefit people with chronic heart failure? BMJ 2011;342:d234.
22. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
23. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Betaagonists. J Am Coll Cardiol 2011;57:2127-38.
24. Lacasse Y. Review: Cardioselective beta blockers do not produce adverse respiratory effects in COPD. Evid Based Med 2006;11:84.
25. Staszewsky L, Wong M, Masson S, et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail 2007;13:797-804.
26. Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-5.
27. Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-7.
28. Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:d2S49.
29. Matera MG, Martuscelli E, Cazzola M. Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther 2010;23:1-8.
30. Hawkins NM, Wang D, Petrie MC, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 2010;12:557-65.
31. 2 AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol 2011;51:529-33.
32. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-60.
33. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009;10:45.
34. Bartziokas K, Papaioannou Al, Minas M, et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther 2011;24:625-31.